CNSP Stock Forecast: CNS Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 15 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores CNS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (43): The shares have been drifting up relative to others.
Volatility (9): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CNSP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CNSP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Sept 2025 | Maxim Group | Upgrade | Buy | $20 |
| 25 Mar 2025 | Maxim Group | Downgrade | Hold | — |
| 10 Sept 2024 | Maxim Group | Upgrade | Buy | $0.50 |
| 2 Feb 2021 | Brookline Capital | Initiates | Buy | $10 |
| 24 Aug 2020 | Ladenburg Thalmann | Initiates | Buy | — |
| 4 Dec 2019 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
CNSP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CNSP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, CNS Pharmaceuticals, Inc. returned −45.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CNSP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 84% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −106.6%
- Return on assets
- −58.0%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CNS Pharmaceuticals, Inc. has a market value of $5.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$16.7M.
Free cash flow in the twelve months to 30 June 2026: −$13.4M.
CNS Pharmaceuticals, Inc. spent $1K on share buybacks in the twelve months to 30 June 2026.
CNS Pharmaceuticals, Inc. employs 8 people.
Data provided by Twelve Data
CNSP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CNSP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own CNS Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CNSP
How does Ticker Nerd's model rank CNSP?
As at 21 Nov 2026, CNS Pharmaceuticals, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (43 of 100).
What is the CNSP stock forecast for 2030?
No analyst covering CNS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
How has CNSP stock performed over the past year?
CNS Pharmaceuticals, Inc. returned -45.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CNS Pharmaceuticals, Inc. do?
CNS Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive cancers of the brain and central nervous system. Its current work centers on advancing anti-cancer drug candidates designed to address high-unmet-need diseases such as glioblastoma and other malignant brain tumors.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive cancers of the brain and central nervous system. Its current work centers on advancing anti-cancer drug candidates designed to address high-unmet-need diseases such as glioblastoma and other malignant brain tumors. The company’s pipeline includes investigational compounds such as berubicin and other neurology and oncology assets, reflecting its emphasis on treatments that can reach and act within the central nervous system. CNS Pharmaceuticals Inc. operates in the specialized oncology segment of the pharmaceutical market, where drug development is shaped by the challenges of treating tumors protected by the blood-brain barrier. The company is based in Houston, Texas, and its role in the market is to develop novel hospital- and specialist-directed treatment options for severe brain and CNS cancers.
CEO Mr. Rami Levin M.B.A. · 8 employees · United States · https://cnspharma.com